Literature DB >> 31514696

Association Between Intravenous Thrombolysis and Anaphylaxis Among Medicare Beneficiaries With Acute Ischemic Stroke.

Mackenzie P Lerario1,2, James C Grotta3, Alexander E Merkler1, Setareh Salehi Omran1,4, Monica L Chen1, Neal S Parikh4, Shadi Yaghi5, Santosh Murthy1, Babak B Navi1, Hooman Kamel1.   

Abstract

Background and Purpose- Allergic reactions, including anaphylaxis, can sometimes occur after intravenous thrombolysis in patients with acute ischemic stroke. However, it remains unclear whether patients with stroke who receive thrombolytic agents face a higher risk of anaphylaxis than those who do not receive thrombolytics. Methods- We performed a retrospective cohort study using inpatient and outpatient claims between 2008 and 2015 from a nationally representative 5% sample of Medicare beneficiaries. We included patients who were ≥65 years old and hospitalized with acute ischemic stroke, defined by validated International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. Our exposure was treated with an intravenous thrombolytic agent during the index hospitalization (International Classification of Diseases, Ninth Revision, Clinical Modification code 99.10). Our primary outcome was anaphylaxis, defined using an accepted International Classification of Diseases, Ninth Revision, Clinical Modification code algorithm (989.5, 995.0-4, 995.6x, E905, E905.3, E905.5, or E905.8-9). A secondary outcome was anaphylactic shock (995.0 or 995.6x). Multiple logistic regression was used to evaluate the association between intravenous thrombolysis and anaphylaxis after adjustment for demographics, vascular risk factors, the Charlson comorbidity index, exposure to intravenous contrast dye, treatment with mechanical thrombectomy, and history of allergic reactions. Results- Among 66 989 patients with stroke, the 3176 (4.7%) who underwent intravenous thrombolysis more often had atrial fibrillation (47.7% versus 37.4%) and more often received intravenous contrast dye (44.3% versus 21.9%) but were otherwise similar in terms of demographics and comorbidities. Anaphylaxis developed in 17 (0.54%; 95% CI, 0.31%-0.86%) patients who received intravenous thrombolysis versus 45 (0.07%; 95% CI, 0.05%-0.09%) who did not. After adjustment for demographics, comorbidities, contrast dye, mechanical thrombectomy, and history of allergies, there was a significant association between receipt of intravenous thrombolysis and anaphylaxis (odds ratio, 7.8; 95% CI, 4.3-13.9). We found a similar association for anaphylactic shock. Conclusions- Although a rare occurrence, the risk of anaphylaxis among patients with acute ischemic stroke was significantly higher among those who received intravenous thrombolysis.

Entities:  

Keywords:  anaphylaxis; angioedema; atrial fibrillation; medicare; risk factors

Mesh:

Year:  2019        PMID: 31514696      PMCID: PMC6863087          DOI: 10.1161/STROKEAHA.119.026861

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

1.  Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.

Authors:  C Pechlaner; E Knapp; C J Wiedermann
Journal:  Blood Coagul Fibrinolysis       Date:  2001-09       Impact factor: 1.276

2.  A patient with anaphylaxis after alteplase infusion.

Authors:  J N Cheng; A Lee; J Jannes; R J Heddle; S A Koblar
Journal:  J Clin Neurosci       Date:  2011-11-17       Impact factor: 1.961

Review 3.  2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  William J Powers; Alejandro A Rabinstein; Teri Ackerson; Opeolu M Adeoye; Nicholas C Bambakidis; Kyra Becker; José Biller; Michael Brown; Bart M Demaerschalk; Brian Hoh; Edward C Jauch; Chelsea S Kidwell; Thabele M Leslie-Mazwi; Bruce Ovbiagele; Phillip A Scott; Kevin N Sheth; Andrew M Southerland; Deborah V Summers; David L Tirschwell
Journal:  Stroke       Date:  2018-01-24       Impact factor: 7.914

4.  Algorithm for the diagnosis of anaphylaxis and its validation using population-based data on emergency department visits for anaphylaxis in Florida.

Authors:  Laurel Harduar-Morano; Michael R Simon; Sharon Watkins; Carina Blackmore
Journal:  J Allergy Clin Immunol       Date:  2010-06-11       Impact factor: 10.793

5.  Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients.

Authors:  B R Reed; A B Chen; P Tanswell; W S Prince; R M Wert; L Glaesle-Schwarz; E B Grossbard
Journal:  Thromb Haemost       Date:  1990-10-22       Impact factor: 5.249

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 7.  Anaphylactic shock associated with intravenous thrombolytics.

Authors:  Amna Zarar; Asif A Khan; Malik M Adil; Adnan I Qureshi
Journal:  Am J Emerg Med       Date:  2013-09-30       Impact factor: 2.469

8.  Orolingual Angioedema During or After Thrombolysis for Cerebral Ischemia.

Authors:  Fjorda Myslimi; François Caparros; Nelly Dequatre-Ponchelle; Solène Moulin; Sophie Gautier; Patrick Girardie; Charlotte Cordonnier; Régis Bordet; Didier Leys
Journal:  Stroke       Date:  2016-05-19       Impact factor: 7.914

9.  Validating administrative data in stroke research.

Authors:  David L Tirschwell; W T Longstreth
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

Review 10.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.

Authors:  Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

View more
  1 in total

1.  Serum of limb remote ischemic postconditioning inhibits fMLP-triggered activation and reactive oxygen species releasing of rat neutrophils.

Authors:  Gangling Chen; Jiangwei Zhang; Mingyue Sheng; Sanli Zhang; Qi Wu; Lei Liu; Boyang Yu; Junping Kou
Journal:  Redox Rep       Date:  2021-12       Impact factor: 4.412

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.